Efficacy and Safety of Bevacizumab Biosimilar FKB238 Versus Originator Bevacizumab: Results from AVANA, a Phase III Trial in Patients with Non-Squamous Non-Small-Cell Lung Cancer (non-sq-NSCLC).

Syrigos K, Abert I, Andric Z, Bondarenko IN, Dvorkin M, Galic K, Galiulin R, Kuchava V, Sriuranpong V, Trukhin D, Zhavrid E, Fu D, Kassalow LM, Jones S, Bashir Z, AVANA Investigators

Open source

DOI: 10.1007/s40259-021-00489-4
Published: 2021 Jul
Container: BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1007/s40259-021-00489-4,
  title = {Efficacy and Safety of Bevacizumab Biosimilar FKB238 Versus Originator Bevacizumab: Results from AVANA, a Phase III Trial in Patients with Non-Squamous Non-Small-Cell Lung Cancer (non-sq-NSCLC).},
  author = {Syrigos K and Abert I and Andric Z and Bondarenko IN and Dvorkin M and Galic K and Galiulin R and Kuchava V and Sriuranpong V and Trukhin D and Zhavrid E and Fu D and Kassalow LM and Jones S and Bashir Z and AVANA Investigators},
  year = {2021},
  journal = {BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy},
  doi = {10.1007/s40259-021-00489-4},
  url = {https://doi.org/10.1007/s40259-021-00489-4}
}

RIS

TY  - JOUR
TI  - Efficacy and Safety of Bevacizumab Biosimilar FKB238 Versus Originator Bevacizumab: Results from AVANA, a Phase III Trial in Patients with Non-Squamous Non-Small-Cell Lung Cancer (non-sq-NSCLC).
AU  - Syrigos K
AU  - Abert I
AU  - Andric Z
AU  - Bondarenko IN
AU  - Dvorkin M
AU  - Galic K
AU  - Galiulin R
AU  - Kuchava V
AU  - Sriuranpong V
AU  - Trukhin D
AU  - Zhavrid E
AU  - Fu D
AU  - Kassalow LM
AU  - Jones S
AU  - Bashir Z
AU  - AVANA Investigators
PY  - 2021
JO  - BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy
DO  - 10.1007/s40259-021-00489-4
UR  - https://doi.org/10.1007/s40259-021-00489-4
ER  -

APA

K, S., I, A., Z, A., IN, B., M, D., K, G., R, G., V, K., V, S., D, T., E, Z., D, F., LM, K., S, J., Z, B., & Investigators, A. (2021). Efficacy and Safety of Bevacizumab Biosimilar FKB238 Versus Originator Bevacizumab: Results from AVANA, a Phase III Trial in Patients with Non-Squamous Non-Small-Cell Lung Cancer (non-sq-NSCLC).. BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy. https://doi.org/10.1007/s40259-021-00489-4

Source records

pubmed · retrieved 2026-09-26T02:19:59.264Z